Demcizumab

{
  "id": "MLC-T-ONC-012960",
  "term": "Demcizumab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized monoclonal antibody directed against the N-terminal epitope of Notch ligand DLL4 (delta-like 4) with potential antineoplastic activity. Demcizumab binds to the membrane-binding portion of DLL4 and prevents its interaction with Notch-1 and Notch-4 receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated into the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium.",
  "synonyms": [
    "anti-delta-like 4 monoclonal antibody OMP-21M18",
    "anti-DLL4 monoclonal antibody OMP-21M18"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/demcizumab/"
}